đź’¨ Abstract

Nektar Therapeutics (NKTR) reported a first-quarter loss of $50.9 million, or 24 cents per share, missing Wall Street's expectations for a loss of 18 cents per share. Adjusted losses were 22 cents per share. The company's revenue of $10.5 million also fell short of the anticipated $17.6 million.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖

Powered by MessengerX.io